BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Abstract Bromodomain and extra-terminal tail (BET) proteins have been identified as potential epigenetic targets in cancer, including glioblastoma. These epigenetic modifiers link the histone code to gene transcription that can be disrupted with small molecule BET inhibitors (BETi). With the aim of...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-12-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-022-05497-y |